SCHEMBL5647344

SCHEMBL5647344

CCNC(=O)COc1ccc(Cl)cc1CNC(=O)Cc1c(C)ccn(NCc2cccnc2N2CCOCC2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 5/20 0.45
PRSS1 P07477 4/20 0.45
PRSS2 P07478 4/20 0.45
PRSS3 P35030 4/20 0.45
SCN10A Q9Y5Y9 2/20 0.42
SCN2A Q99250 1/20 0.42
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
ANO1 Q5XXA6 1/20 0.38
ANO2 Q9NQ90 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MCHR1 Q99705 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650557 0.90 TSHR (0.48) F2PRSS1PRSS2PRSS3SCN10A
SCHEMBL5646352 0.87 SCN10A (0.46) F2PRSS1PRSS2PRSS3SCN10A
SCHEMBL5651637 0.86 F2 (0.46) F2PRSS1PRSS2PRSS3KDM4E
SCHEMBL5648817 0.85 F2 (0.48) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5650277 0.83 F2 (0.51) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5650131 0.82 F2 (0.52) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5650742 0.82 F2 (0.51) F2PRSS1PRSS2PRSS3KDM4E
SCHEMBL5651509 0.82 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL5648295 0.81 ANO1 (0.48) F2PRSS1PRSS2PRSS3LMNA
SCHEMBL5645845 0.81 F2 (0.48) F2PRSS1PRSS2PRSS3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin ASTRAZENECA AB (SE) 2007-07-12 US disclosed
EP-1713774-A1 NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN AstraZeneca AB (SE) 2006-10-25 EP disclosed
WO-2005075424-A1 NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN ASTRAZENECA AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin PLG, F2, PLAT F2 2/4885PRSS1 20/4885PRSS2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.